Europe postpones decision on Bristol immune system cancer drug

LONDON, March 27 (Reuters) - European regulators have postponed a decision on whether to recommend approval of a closely watched Bristol-Myers Squibb drug that helps the immune system fight cancer, a spokeswoman for the European Medicines Agency said on Friday.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.